Dive into the Biopharma Space

Private bio/pharma funding in 2025 totaled approximately $40.0 B  across 1,045 private funding events, slightly below 2024’s $40.4 B , but substantially below 2024’s 1,367  deals (FN1). Activity was heavily front-loaded, with January 2025  alone accounting for $6.3 B  and 138 deals , the single most active month of the year.  After a mid-year lull in deal volume and capital deployment, the market saw modest late-year momentum, particularly in October ($6.0 B) and December ($3

After a difficult 3 years of private biotech funding for early-stage biotech companies (FN1, FN2), we predict that 2026 will be a breakout year. Why? 1. Public smid-cap biotech stocks soared in the 2nd half of 2025; 2. Historical data shows that when public smid-cap biotech stocks soar, the biotech IPO market opens up the following year; 3. Once the biotech IPO market opens, private funding should follow in subsequent quarters 1. Public smid-cap biotech stocks soared in the 2

Europe has rapidly become one of the world’s most dynamic regions for genetic analysis, sequencing technologies, and data-driven precision medicine. From liquid biopsies and transplant monitoring to next-generation bioinformatics platforms, a wave of innovative companies is redefining how genetic data is generated, interpreted, and applied in real clinical settings. At BiopharmIQ , we track 141 active European companies operating in genetic analysis, sequencing, and enablin

Seattle continues to make waves in the life sciences arena, blending the city’s deep research heritage with a new generation of biotech innovation. From next-generation antibody-drug conjugates to advanced RNA vaccines, the Emerald City is home to companies pushing the boundaries of how we diagnose, treat, and understand disease. Here are 10 companies to watch in 2025 , each driving fresh breakthroughs through clinical success, funding momentum, or technological innovation.

Southern California has long been known for its beaches and biotech, and nowhere is the region’s innovation more evident than in its antibody ecosystem . From San Diego’s wet labs  to Pasadena’s protein engineers , the area has become a proving ground for companies blending creativity, capital, and clinical progress. At BiopharmIQ, we’ve tracked more than a hundred SoCal bio/pharma's developing antibody-based drugs, and we’ve handpicked 10 companies to watch in 2025 , chosen

" Private bio/pharma funding activity strengthened in September, reaching its highest level since early 2025 and reflecting a gradual re-acceleration in deal flow. " September 2025 marks the end of the third quarter with a significant uptick in deal activity , even though total dollars raised remain below early-year highs. The market continues to favor non-dilutive funding and smaller financings, with grants leading by deal count  and early-stage rounds bouncing back  from th

At BiopharmIQ , we’ve mapped over 280 biotech and pharma companies in Texas, tracking the rapid evolution of one of the most dynamic innovation hubs in the U.S. What once was a regional life sciences cluster is now a full-fledged ecosystem, where emerging bio/pharmas, mid-sized innovators, and major pharmaceutical players converge. This year’s landscape highlights clinical-stage activity, late preclinical acceleration, and significant capital infusions across therapeutic are

At BiopharmIQ , we’ve mapped 377 companies in the global AAV landscape . This work gave us a broad view of the ecosystem, from vector engineering innovators to clinical-stage pioneers and emerging players in new geographies. While big pharma has made major moves into AAV, this list focuses on bio/pharmas and mid-sized innovators  that stand out for their technology novelty, recent funding, promising clinical results, or regulatory momentum . Do you have them on your radar? 👁

"Private bio/pharma funding rebounded in value in August, though deal counts remain subdued." August 2025 marked the seventh consecutive...

Radiopharmaceuticals are rapidly gaining attention across the biopharma industry, combining targeted delivery with therapeutic...

Cell therapy continues to be one of the most dynamic segments of biotech and pharma financing in 2025. From oncology to neurology,...

2025 Bio/Pharma Funding Trends: July’s Update

“Bio/pharma funding deal data in H1 2025 reveals a troubling downward shift starting in February.” Investment in bio/pharma was down in...

A Step-by-Step Guide to Exporting Data Efficiently and Understanding Credit Usage Whether you’re building prospect lists, prepping for...

Whether you're mapping the antibody development landscape, identifying partnership opportunities, or sourcing leads in immunotherapy,...

In Q1 2025, 26 new and emerging bio/pharma companies were identified, with the majority based in the U.S.—California and Massachusetts leading the count. Most of these companies focus on therapeutics, signaling strong investor interest. Verdiva Bio topped funding with $411M, followed by Kardigan and Windward Bio. Explore geographic trends, sector focus, and top-funded startups in our latest biopharmIQ report.

Whether you’re scouting investment trends, tracking competitors, or preparing reports for market research or investor outreach,...

Whether you're scouting Phase 3 candidates for partnership or identifying innovative early-stage biotech startups, BiopharmIQ’s clinical...

Gene editing has emerged as one of the most transformative technologies in biotech and pharma, with applications spanning therapeutics,...

BiopharmIQ is designed to empower sales and marketing professionals in the life sciences industry with targeted lists of companies and...